Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
Bracco Diagnostics, Inc
MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is believed that using MultiHance may be able to help doctors tell normal liver cells apart from active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve the way patients with hepatocellular carcinoma are managed clinically.
We hypothesize that the Multi-Hance contrast material will provide better image definition of treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast agents.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.
International Normalized Ratio (INR) \<1.4
Platelet count \> 80,000
You may not be if
Contraindications to TACE procedure
Unable to have an MRI Scan
Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol
Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders
Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate\<15cc/min)
